Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches
Status:
Completed
Trial end date:
2021-04-14
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled study. Subjects who meet the entry criteria will
be randomized o receive one of three blinded treatments [C213 1.9 mg patch and placebo patch;
C213 3.8 mg (1.9 mg x 2 patches), two placebo patches] on Day 1 and will have up to 48 weeks
to confirm and treat a cluster headache. Subjects will self-administer the patches and
respond to questions in the electronic diary (eDiary) until 1-hour post treatment
administration.